About Us

Roquefort Therapeutics plc is listed on the London Stock Exchange (LSE:ROQ). We are a team of senior executives with significant experience in establishing and growing businesses in the private and public sectors. Roquefort Therapeutics plc was established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders.

In December 2021 we acquired the entire issued share capital of Lyramid Pty Ltd, an Australian company that has an exclusive global licence from Cellmid Limited, the holder of the largest patent portfolio covering composition of matter and methods patents around Midkine, a novel disease target.

IF YOU HAVE ANY QUESTIONS, PLEASE GET IN TOUCH